3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Neuroendocrine Tumors
3
Gastro-enteropancreatic neuroendocrine tumor
2
Pheochromocytoma
1
Paraganglioma
1
Pancreatic Neoplasms
1
Carcinoid Tumor
1
Adenoma, Islet Cell
1
Acromegaly
1
Interventions
Specimen Handling
4
Magnetic Resonance Spectroscopy
4
Temozolomide
3
sargramostim
2
montanide ISA 51
2
lutetium Lu 177 dotatate
2
incomplete Freund's adjuvant
2
Sunitinib
2
Octreotide
2
Everolimus
2
Colony-Stimulating Factors
2
Capecitabine
2
sapanisertib
1
lanreotide
1
fludarabine phosphate
1
cabozantinib
1
belzutifan
1
atezolizumab
1
aflibercept
1
abemaciclib
1
X-Rays
1
Salts
1
Phantoms, Imaging
1
PM 01183
1
Methods
1
LY2940680
1
Interleukin-13
1
Injections
1
Immunoglobulin G
1
Fulvestrant
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenoma, Islet Cell
×
lanreotide
×
1 year
×
Clear all
NCT05477576
2026-03-30
ACTION-1
RayzeBio, Inc.
Phase 3
Recruiting
338 enrolled